The latter used murine models for treatment with the specific sphingosine kinase 1 (SphK1) inhibitor (SK1-I) which successfully suppressed S1P levels, reduced metastases, and decreased the overall tumor burden [34,35]. The gene discussed is SPHK1; the disease is neoplasm.